EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
Protein tyrosine kinases of the human epidermal growth factor receptor family, including
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
F Skoulidis, JV Heymach - Nature Reviews Cancer, 2019 - nature.com
The impressive clinical activity of small-molecule receptor tyrosine kinase inhibitors for
oncogene-addicted subgroups of non-small-cell lung cancer (for example, those driven by …
oncogene-addicted subgroups of non-small-cell lung cancer (for example, those driven by …
[HTML][HTML] Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer
Background Human epidermal growth factor receptor 2 (HER2)–targeted therapies have not
been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and …
been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and …
Understanding and targeting resistance mechanisms in NSCLC
J Rotow, TG Bivona - Nature Reviews Cancer, 2017 - nature.com
The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …
Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors
HER2-targeted therapies are approved only for HER2-positive breast and gastric cancers.
We assessed the safety/tolerability and activity of the novel HER2-targeted antibody–drug …
We assessed the safety/tolerability and activity of the novel HER2-targeted antibody–drug …
[HTML][HTML] Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 …
M Riudavets, I Sullivan, P Abdayem, D Planchard - ESMO open, 2021 - Elsevier
Non-small-cell lung cancer (NSCLC) harbouring HER2 alterations is now considered a
distinct molecular subtype. The activation of HER2 in NSCLC occurs via three mechanisms …
distinct molecular subtype. The activation of HER2 in NSCLC occurs via three mechanisms …
Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies
Tumor genetic testing is standard of care for patients with advanced lung adenocarcinoma,
but the fraction of patients who derive clinical benefit remains undefined. Here, we report the …
but the fraction of patients who derive clinical benefit remains undefined. Here, we report the …
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
Purpose Human epidermal growth factor receptor 2 (HER2, ERBB2)–activating mutations
occur in 2% of lung cancers. We assessed the activity of ado-trastuzumab emtansine, a …
occur in 2% of lung cancers. We assessed the activity of ado-trastuzumab emtansine, a …
[HTML][HTML] Comprehensive molecular profiling of lung adenocarcinoma
Cancer Genome Atlas Research Network - Nature, 2014 - ncbi.nlm.nih.gov
Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report
molecular profiling of 230 resected lung adenocarcinomas using messenger RNA …
molecular profiling of 230 resected lung adenocarcinomas using messenger RNA …
Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study
C Zhou, X Li, Q Wang, G Gao, Y Zhang… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Targeted therapies against non–small-cell lung cancer (NSCLC) harboring
HER2 mutations remain an unmet need. In this study, we assessed the efficacy and safety of …
HER2 mutations remain an unmet need. In this study, we assessed the efficacy and safety of …